Author/Authors :
Liu, Hongai Jinan University - College of Pharmacy, Institute of Genomic Medicine, China , Sun, Hanxiao Jinan University - College of Pharmacy, Institute of Genomic Medicine, China , Li, Lu Jinan University - College of Pharmacy, Institute of Genomic Medicine, China , Mo, Xuemei Jinan University - College of Pharmacy, Institute of Genomic Medicine, China , Li, Xiuying Jinan University - College of Pharmacy, Institute of Genomic Medicine, China , Zhang, Guang Jinan University - College of Pharmacy, Institute of Genomic Medicine, China
Abstract :
Purpose: The aim of the present study was to develop peptide H9 as an efficient antagonist of human cytomegalovirus (HCMV) chemokine receptor US28. Methods: US28 gene was amplified from HCMV, and a stable expression system was constructed using NIH/3T3 cells. Interaction between peptide H9 and receptor US28 was tested by enzyme-linked immunosorbent assay. Flow cytometry was used to determine intracellular concentrations of Ca^2+, and the possible role of H9 as an antagonist was evaluated by anti-viral experiments. Results: H9 interacts with the US28 receptor and prevents an increase of Ca^2+ resulting from an interaction of chemokine with its receptor. Anti-viral assays showed that H9 could inhibit cytopathic effects of HCMV. AD169 infection (EC50 = 0.46 ng/ml), and the production of pp65 antigen were strongly inhibited with an EC50 value of 0.34 ng/ml. Conclusion: The results demonstrate that H9 is an antagonist of US28, suggesting a possible role as a treatment for HCMV.
Keywords :
Human cytomegalovirus , US28 , Peptide H9 , Trapping receptor , ligand , Antagonist
